Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor
NCT01765049 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 260
Last updated 2022-10-18
Summary
Breast density change after short term use of aromatase inhibitor in postmenopausal ER positive breast cancer would predict endocrine responsiveness
Conditions
- Invasive Breast Cancer
- Estrogen Receptor Positive Breast Cancer
Sponsors & Collaborators
-
Seoul National University Hospital
lead OTHER
Principal Investigators
-
Wonshik Han, MD PhD · SNUH
Eligibility
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2025-12-15
- Completion
- 2025-12-15
Countries
- South Korea
Study Locations
More Related Trials
-
Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
NCT01622361 ·Status: UNKNOWN ·Phase: PHASE3
-
Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer
NCT00002646 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Tamoxifen on Breast Density in Premenopausal Women With Breast Cancer or High Risk for Breast Cancer
NCT00086749 ·Status: COMPLETED
-
Analysis of Initial Adherence and Its Impact on Long-term Adherence to Hormonal Therapy for Breast Cancer
NCT03186599 ·Status: UNKNOWN ·Phase: NA
-
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
NCT00542594 ·Status: TERMINATED
-
10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)
NCT00885612 ·Status: COMPLETED
-
Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast
NCT04666805 ·Status: UNKNOWN
-
Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging
NCT05700006 ·Status: COMPLETED
-
Neoadjuvant Combined Endocrine and HER2 Target Therapy in Postmenopausal Women With ER and Her2 Positive Breast Cancer
NCT01275859 ·Status: COMPLETED ·Phase: PHASE2
-
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
NCT05801705 ·Status: UNKNOWN
-
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
NCT05439499 ·Status: UNKNOWN ·Phase: PHASE3
-
Pharmacology of Adjuvant Hormonotherapy in Breast Cancer
NCT01127295 ·Status: COMPLETED ·Phase: PHASE4
-
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
NCT02598557 ·Status: COMPLETED ·Phase: PHASE2
-
A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
NCT00544986 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of Aromatase Inhibitors on Cardiovascular Risk Factors in Women With Breast Cancer
NCT01080170 ·Status: COMPLETED
-
Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative Endocrinotherapy
NCT01613560 ·Status: UNKNOWN ·Phase: PHASE2
-
Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+
NCT01220076 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer
NCT03351062 ·Status: RECRUITING ·Phase: PHASE3
-
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
NCT01781338 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer
NCT02097459 ·Status: UNKNOWN ·Phase: PHASE3
-
A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients
NCT03543059 ·Status: UNKNOWN
-
Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study
NCT00653718 ·Status: COMPLETED
-
Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD
NCT01655004 ·Status: UNKNOWN ·Phase: NA
-
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
NCT02278120 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3 Comparative Study of TAP-144-SR(6M) in Postoperative and Hormone Therapy-naïve Patients With Premenopausal Breast Cancer
NCT01546649 ·Status: COMPLETED ·Phase: PHASE3